SecurityPFIS / Peoples Financial Services Corp. (711040105)
President & CEOBEST CRAIG W
IndustryNational Commercial Banks
Institutional Owners66
Institutional Shares2,089,330 - 28.24%
Common Shares Outstanding7,399,054 shares (as of 2018-06-30)
Institutional Value$ 230,858,000 USD

Institutional Stock Ownership and Shareholders

PFIS / Peoples Financial Services Corp. Institutional Ownership

Peoples Financial Services Corp. (NASDAQ:PFIS) has 66 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,089,330 shares. Largest shareholders include BlackRock Inc., Peoples Financial Services Corp., Vanguard Group Inc, BlackRock Fund Advisors, State Street Corp, Franklin Resources Inc, Northern Trust Corp, Pnc Financial Services Group, Inc., BlackRock Institutional Trust Company, N.A., and Geode Capital Management, Llc.
Peoples Financial Services Corp. (NASDAQ:PFIS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-07-24 13F-HR Janney Montgomery Scott LLC 0 7,126 0 335
2018-08-14 13F-HR Jacobi Capital Management LLC 1,800 1,800 0.00 81 85 4.94
2018-08-10 13F-HR Legal & General Group Plc 1,264 1,043 -17.48 58 49 -15.52
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 26,927 26,686 -0.90 1,229 1,255 2.12
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 9,341 0 439
2018-08-13 13F-HR HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 8,633 0 -100.00 394 0 -100.00
2017-10-26 13F-HR Acrospire Investment Management LLC 100 0 -100.00 4 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 30,034 29,819 -0.72 1,224 1,452 18.63
2018-08-14 13F-HR VANGUARD GROUP INC 239,779 253,316 5.65 10,946 11,911 8.82
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 5,391 5,174 -4.03 246 243 -1.22
2018-08-06 13F-HR STRS OHIO 1,300 2,100 61.54 59 98 66.10
2018-08-14 13F-HR BROWN BROTHERS HARRIMAN & CO 8,000 8,000 0.00 365 376 3.01
2018-07-26 13F-HR Advisornet Financial, Inc 2,000 2,000 0.00 91 94 3.30
2018-07-26 13F-HR Sterling Investment Advisors, Ltd. 1,004 1,004 0.00 46 47 2.17
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 500 500 0.00 22 24 9.09
2018-08-14 13F-HR FRANKLIN RESOURCES INC 87,543 87,543 0.00 3,996 4,116 3.00
2018-07-16 13F-HR Sabal Trust CO 7,737 7,737 0.00 353 364 3.12
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 4,380 4,487 2.44 200 211 5.50
2018-08-10 13F-HR CITIGROUP INC 1,901 1,629 -14.31 87 77 -11.49
2018-07-11 13F-HR DENALI ADVISORS LLC 48 0 -100.00 2 0 -100.00
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 5,500 5,500 0.00 251 259 3.19
2018-08-13 13F-HR Vantage Investment Advisors, LLC 200 0 -100.00 9 0 -100.00
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 58,935 62,879 6.69 2,690 2,956 9.89
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 1,390 247 -82.23 63,454 11,614 -81.70
2018-08-14 13F-HR ROYAL BANK OF CANADA 658 670 1.82 30 32 6.67
2018-07-25 13F-HR BESSEMER GROUP INC 2,600 2,600 0.00 119 122 2.52
2018-08-14 13F-HR JP Morgan Chase & Co 1,380 1,673 21.23 63 79 25.40
2018-08-13 13F-HR Renaissance Technologies LLC 35,800 1,634
2018-08-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 1,090 0 -100.00 50 0 -100.00
2018-08-07 13F-HR SG Americas Securities, LLC 0 2,705 0 127
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 676 676 0.00 31 32 3.23
2018-08-15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 2,467 2,467 0.00 112,618 115,998 3.00
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 2,763 1,651 -40.25 126 77 -38.89
2018-08-14 13F-HR UBS Group AG 783 1,153 47.25 36 54 50.00
2018-07-23 13F-HR Stone House Investment Management, LLC 29,430 29,436 0.02 1,343 1,384 3.05
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 99 99 0.00 5 4,655 93,000.00
2018-08-13 13F-HR ALLIANCEBERNSTEIN L.P. 4,600 4,800 4.35 210 226 7.62
2018-05-11 13F-HR MARTINGALE ASSET MANAGEMENT L P 7,001 7,001 0.00 327 320 -2.14
2018-08-14 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 40,275 40,275 0.00 1,839 1,894 2.99
2018-08-14 13F-HR Voya Investment Management LLC 4,950 4,376 -11.60 226 206 -8.85
2018-07-20 13F-HR Creative Planning 9,816 9,393 -4.31 448 442 -1.34
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 0 371 0 17
2018-07-10 13F-HR PEOPLES FINANCIAL SERVICES CORP. 321,418 315,538 -1.83 14,672 14,837 1.12
2018-07-27 13F-HR Riggs Asset Managment Co. Inc. 5,549 5,549 0.00 253 261 3.16
2018-08-14 13F-HR STATE STREET CORP 125,961 126,235 0.22 5,750 5,935 3.22
2018-08-14 13F-HR TEACHERS ADVISORS INC 11,685 11,685 0.00 533 549 3.00
2017-02-10 13F-HR BlackRock Fund Advisors 193,079 225,276 16.68 7,870 10,971 39.40
2018-09-18 13F-HR/A NORTHERN TRUST CORP 72,020 76,000 5.53 3,287 3,574 8.73
2018-08-14 13F-HR BARCLAYS PLC 1,429 503 -64.80 65 23 -64.62
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 120 6
2018-08-15 13F-HR Metlife Investment Advisors, Llc 3,673 3,673 0.00 168 173 2.98
2018-08-07 13F-HR IFP Advisors, Inc 305 305 0.00 14 14 0.00
2018-08-10 13F-HR Krasney Financial LLC 5,405 5,405 0.00 247 254 2.83
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 4,409 207
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 18,918 16,432 -13.14 864 773 -10.53
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 12,574 11,878 -5.54 574 559 -2.61
2018-08-06 13F-HR RHUMBLINE ADVISERS 6,054 6,759 11.65 276 318 15.22
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 68,037 67,499 -0.79 2,773 3,287 18.54
2018-08-14 13F-HR MORGAN STANLEY 24,941 23,927 -4.07 1,138 1,125 -1.14
2018-05-11 13F-HR CITIGROUP INC 2,853 1,901 -33.37 133 87 -34.59
2018-08-09 13F-HR MARTINGALE ASSET MANAGEMENT L P 7,001 7,001 0.00 320 330 3.13
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 49 2
2018-07-12 13F-HR Community Bank, N.A. 1,218 1,218 0.00 56 57 1.79
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 7,900 7,900 0.00 361 371 2.77
2018-08-09 13F-HR BlackRock Inc. 336,206 349,665 4.00 15,348 16,441 7.12
2018-08-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 98 96 -2.04 4 5 25.00
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 26,443 33,618 27.13 1,208 1,581 30.88
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 10,437 10,543 1.02 476 496 4.20
2018-08-08 13F-HR LSV ASSET MANAGEMENT 6,100 6,100 0.00 278 286 2.88
2018-08-14 13F-HR DEUTSCHE BANK AG\ 7,711 12,366 60.37 350 580 65.71
2018-07-17 13F-HR BERKSHIRE ASSET MANAGEMENT LLC/PA 17,791 17,791 0.00 812 837 3.08
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 66,981 74,265 10.87 3,058 3,491 14.16
2017-02-10 13F-HR BlackRock Advisors LLC 2,533 2,547 0.55 103 124 20.39

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

BRIEF-Peoples Financial Services Q1 Core Earnings Per Share $0.79

2018-04-25 reuters
* PEOPLES FINANCIAL SERVICES - TAX-EQUIVALENT NET INTEREST INCOME FOR 3 MONTHS ENDED MARCH 31 WAS UP $942 THOUSAND TO $17.6 MILLION FROM $16.7 MILLION IN 2017 Source text for Eikon: Further company coverage: (1-0)

CUSIP: 711040105